Published in Case Rep Oncol on August 09, 2012
Anal cancer treatment: current status and future perspectives. World J Gastroenterol (2015) 0.97
Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis. Radiat Oncol (2014) 0.86
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer (2016) 0.78
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Sci Rep (2016) 0.75
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. Sci Rep (2017) 0.75
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol (2005) 4.16
Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie (2006) 1.90
Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology (2009) 1.27
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer (1999) 1.10
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med (1989) 1.09
Metastatic anal cancer: the search for cure. Onkologie (2006) 1.06
K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol (2009) 1.01
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol (1993) 0.91
Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer. Colorectal Dis (2003) 0.85
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology (2007) 2.27
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2006) 2.15
Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol (2005) 2.04
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 1.70
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer (2006) 1.65
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica (2011) 1.63
Rare phenomenon: liver metastases from glioblastoma multiforme. J Clin Oncol (2011) 1.60
Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab (2006) 1.55
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica (2005) 1.44
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch (2010) 1.42
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res (2004) 1.28
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology (2005) 1.28
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res (2010) 1.23
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology (2009) 1.16
Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood (2005) 1.16
Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg (2008) 1.15
MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab (2012) 1.11
Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab (2008) 1.10
WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol (2007) 1.06
Well-differentiated gastric tumors/carcinomas. Neuroendocrinology (2007) 1.06
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer (2008) 1.04
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol (2006) 1.02
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid (2013) 1.02
Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol (2008) 1.01
Correlation of Helicobacter pylori virulence genotypes vacA and cagA with histological parameters of gastritis and patient's age. Mod Pathol (2007) 0.98
SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling. Endocr Relat Cancer (2010) 0.98
PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus. Diagn Mol Pathol (2003) 0.98
Tyramide signal amplification for DNA and mRNA in situ hybridization. Methods Mol Biol (2006) 0.98
Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer (2002) 0.97
Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. Am J Surg Pathol (2006) 0.93
Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer (2003) 0.91
Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer (2007) 0.91
Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci (2004) 0.90
Loss of heterozygosity at chromosome 6q23-25 correlates with clinical and histologic parameters in salivary gland adenoid cystic carcinoma. Virchows Arch (2002) 0.89
Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch (2007) 0.88
MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol (2014) 0.88
ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology (2010) 0.87
Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. Virchows Arch (2003) 0.87
Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene (2002) 0.86
Paraneoplastic Necrotizing Myopathy with a Mild Inflammatory Component: A Case Report and Review of the Literature. Case Rep Oncol (2010) 0.86
Poorly differentiated oncocytic thyroid carcinoma--diagnostic implications and outcome. Histopathology (2012) 0.85
A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas. J Clin Endocrinol Metab (2004) 0.85
Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol (2005) 0.84
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells. Exp Hematol (2004) 0.84
Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol (2011) 0.83
Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res (2004) 0.83
Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure. Ann Hematol (2011) 0.82
Assessment of Helicobacter pylori clarithromycin resistance mutations in archival gastric biopsy samples. Swiss Med Wkly (2005) 0.82
The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells. Antivir Ther (2007) 0.82
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. Neuroendocrinology (2014) 0.82
Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol (2009) 0.81
Inverse response of leukocyte heat shock proteins and DNA damage to exercise and heat. Free Radic Res (2003) 0.81
DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. Diagn Mol Pathol (2003) 0.80
Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics (2003) 0.80
CARD In Situ Hybridization: Sights and Signals. Endocr Pathol (1999) 0.79
Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathology (2013) 0.77
Increased red cell corpuscular volume and hepatic mitochondrial function in NRTI-treated HIV infected patients. Curr HIV Res (2009) 0.77
Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol (2013) 0.76
Familial pheochromocytomas and paragangliomas: stories from the sign-out room. Endocr Pathol (2006) 0.76
Cerebrospinal fluid pleocytosis: pitfalls and benefits of combined analysis using cytomorphology and flow cytometry. Cancer Cytopathol (2011) 0.76
Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr Pathol (2003) 0.76
CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res (2004) 0.76
Cutaneous infiltrations can herald an inapparent myelodysplastic syndrome. Acta Derm Venereol (2006) 0.75
Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Arch (2007) 0.75
Multiple Organ Failure in a Young Asylum-Seeker. Dtsch Arztebl Int (2017) 0.75
Neoplastic pericardial effusion induces functional nonvalvular mitral valve stenosis. J Am Coll Cardiol (2010) 0.75
Metastasis of osteosarcoma after 16 years. J Clin Oncol (2010) 0.75
Gastrointestinal stromal tumors in Addis Ababa, Ethiopia. Ethiop Med J (2011) 0.75